白蛋白结合型紫杉醇联合奈达铂诱导化疗对局部晚期鼻咽癌的影响-中国药房

白蛋白结合型紫杉醇联合奈达铂诱导化疗对局部晚期鼻咽癌的影响

请在关注微信后，向客服人员索取文件

篇名：	白蛋白结合型紫杉醇联合奈达铂诱导化疗对局部晚期鼻咽癌的影响
TITLE：	Effects of albumin-bound paclitaxel combined with nedaplatin inductive chemotherapy on loco-regionally advanced nasopharyngeal carcinoma
摘要：	目的观察白蛋白结合型紫杉醇联合奈达铂诱导化疗后再行同步放化疗治疗局部晚期鼻咽癌的临床效果和安全性。方法回顾性分析我院2017年8月－2018年7月接受白蛋白结合型紫杉醇联合奈达铂诱导化疗的局部晚期鼻咽癌（Ⅲ/Ⅳa期）患者临床资料（观察组，45例），采用倾向性评分匹配同期完成多西他赛联合顺铂及氟尿嘧啶方案诱导化疗的局部晚期鼻咽癌患者（对照组，45例）。诱导化疗后两组患者均采用调强放射治疗，观察组采用奈达铂同步化疗，对照组采用顺铂同步化疗。对两组患者的临床效果和不良反应发生情况进行比较。结果所有患者均完成治疗及3年随访。诱导化疗后及同步放化疗1、3个月后，两组患者的近期疗效比较，差异均无统计学意义（P＞0.05）；两组患者的3年局部肿瘤控制率和3年无远处转移生存率比较，差异均无统计学意义（P＞0.05）。观察组患者的白细胞减少（3级及以上）发生率显著低于对照组，周围神经毒性发生率显著高于对照组（P＜0.05）；观察组患者血小板减少（2级及以上）、皮疹、呕吐（2级及以上）等发生率较对照组低，但差异无统计学意义（P＞0.05）；两组患者其他不良反应发生率相差不大，组间比较差异无统计学意义（P＞0.05）。结论白蛋白结合型紫杉醇联合奈达铂诱导化疗后再行同步放化疗治疗局部晚期鼻咽癌的疗效确切且不良反应可耐受。
ABSTRACT：	OBJECTIVE To observe the clinical efficacy and safety of albumin-bound paclitaxel combined with nedaplatin inductive chemotherapy followed by concurrent radiochemotherapy in the treatment of loco-regionally advanced nasopharyngeal carcinoma. METHODS The clinical data of 45 patients （observation group ） with loco-regionally advanced nasopharyngeal carcinoma（Ⅲ/Ⅳa stage ）who received albumin-bound paclitaxel combined with nedaplatin inductive chemotherapy in our hospital from August 2017 to July 2018 were retrospectively analyzed. Propensity score was used to match 45 patients（control group ）with loco-regionally advanced nasopharyngeal carcinoma who received docetaxel combined with cisplatin and fluorouracil inductive chemotherapy. After inductive chemotherapy ，both groups received intensity-modulated radiochemotherapy （IMRT）；observation group was additionally given concurrent nedaplatin chemotherapy ，and control groups was given concurrent cisplatin chemotherapy. Clinical efficacy and the incidence of ADR were compared between 2 groups. RESULTS All patients completed treatment and 3-year follow-up. After inductive chemotherapy and 1，3 months after concurrent radiochemotherapy ，there was no statistical significance in short-term response between 2 groups（P＞0.05）. There was no significantly difference in 3-years local control rate and 3-years free from distant metastasis between 2 groups（P＞0.05）. The incidences of leucopenia （grade 3 or above ）in the observation group were significantly lower than those in the control group ，and the incidence of peripheral neuropathy in observation group was higher than that in control group （P＜0.05）. The incidences of thrombocytopenia （grade 2 or above ），rash and vomiting （grade 2 or above ）in the observation group were lower than those in the control group ，but the difference was not statistically significant （P＞0.05）. There was no significant difference in the incidence of other ADR between 2 groups（P＞0.05）. CONCLUSIONS Albumin-bound paclitaxel combined with nedaplatin inductive chemotherapy followed by concurrent chemoradiotherapy in the treatment of loco-regionally advanced nasopharyngeal carcinoma is effective and tolerable ．
期刊：	2022年第33卷第05期
作者：	王峰，王颖，龙斌，舒小镭，李丛，李晓宇
AUTHORS：	WANG Feng，WANG Ying，LONG Bin，SHU Xiaolei ，LI Cong，LI Xiaoyu
关键字：	白蛋白结合型紫杉醇；奈达铂；局部晚期鼻咽癌；诱导化疗；同步放化疗；疗效；安全性
KEYWORDS：	albumin-bound paclitaxel ；nedaplatin；loco-regionally advanced nasopharyngeal carcinoma ；inductive chemotherapy ；
阅读数：	571 次
本月下载数：	10 次

* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！